Ian W. Flinn

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 16 papers. Top paper: “Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia”.

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine(2013)10.1056/nejmoa1215637

N/A

18.9DataRank · unranked

2265 citations

Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie A. Blum +16 more

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-2856

N/A

4.5DataRank · unranked

184 citations

Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum +9 more

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3706

N/A

4.4DataRank · unranked

198 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

New England Journal of Medicine(2017)10.1056/nejmoa1707447

N/A

1.3DataRank · unranked

5812 citations

Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson +41 more

Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997

Journal of Clinical Oncology(2007)10.1200/jco.2006.08.0762

N/A

0.900DataRank · unranked

402 citations

Donna S. Neuberg, Michael R. Grever, Gordon W. Dewald, John M. Bennett, Elisabeth M. Paietta +6 more

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Journal of Clinical Oncology(2021)10.1200/jco.21.00807

N/A

0.816DataRank · unranked

229 citations

John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi +16 more

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood(2025)10.1182/blood.2024024476

N/A

0.710DataRank · unranked

42 citations

Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn +22 more

ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia

Blood(2025)10.1182/blood.2024027460

N/A

0.345DataRank · unranked

9 citations

Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael Maris, Paolo Ghia +9 more

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Blood(2023)10.1182/blood-2023-186145

N/A

0DataRank · unranked

0 citations

Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel +17 more

A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0028

N/A

0DataRank · unranked

47 citations

Sagar Lonial, Amanda F. Cashen, Manali Kamdar, Ian W. Flinn, Susan O’Brien +15 more

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Haematologica(2024)10.3324/haematol.2024.285754

N/A

0DataRank · unranked

13 citations

Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda +30 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017.v1

N/A

0DataRank · unranked

0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels

Cancers(2021)10.3390/cancers13112828

N/A

0DataRank · unranked

13 citations

Eric C. Frey, Heather A. Jacene, Brad S. Kahl, Steven Piantadosi, Jesus A. Bianco +8 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017

N/A

0DataRank · unranked

0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

Leukemia(2021)10.1038/s41375-021-01328-9

N/A

0DataRank · unranked

183 citations

Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji +35 more

ZUMA‐24: A PHASE 2, OPEN‐LABEL STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA GIVEN OUTPATIENT WITH CORTICOSTEROIDS

Hematological Oncology(2023)10.1002/hon.3166_ot23

N/A

0DataRank · unranked

0 citations

Michael Tees, Ian W. Flinn, Tulio E. Rodriguez, J. Baird, Abhinav Deol +13 more